Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
August 23, 2024 7:50 AM EDTBrookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Conclusions Todays announcement that FDA has approved Modernas new formulation for its COVID-19 vaccine (2024-2025 formulation) targeting the KP.2 variant of SARS-CoV-2, the variant based on guidance from the FDA. This approval follows a... More
